Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

ClinicalTrials.gov ID: NCT02636842

Public ClinicalTrials.gov record NCT02636842. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder.

Study identification

NCT ID
NCT02636842
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
47 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2015 (Type not available)
Primary completion
Jun 2016 (Actual)
Completion
Jun 2016 (Actual)
Last update posted
Jul 14, 2016

2015 – 2016

United States locations

U.S. sites
6
U.S. states
4
U.S. cities
6
Facility City State ZIP Site status
Alkermes Investigational Site Cerritos California 90703 —
Alkermes Investigational Site Lemon Grove California 91945 —
Alkermes Investigational Site Oakland California 94612 —
Alkermes Investigational Site Hoffman Estates Illinois 60169 —
Alkermes Investigational Site Marlton New Jersey 80530 —
Alkermes Investigative Site Dallas Texas 75243 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02636842, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 14, 2016 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02636842 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →